NCT06075953 2026-03-16
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
72 trialsNCT04886531 2026-03-12
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05467891 2026-02-27
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06179303 2026-02-27
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT03179904 2026-02-24
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT06001762 2026-01-16
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT05150652 2026-01-07
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
University of Kentucky
Phase 2 Active not recruiting
NCT05501704 2026-01-07
ETHAN - ET for Male BC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04113863 2025-12-18
ATRA
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT01723774 2025-12-09
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Washington University School of Medicine
Phase 2 Active not recruiting
NCT04569747 2025-11-13
ADEPT
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04553770 2025-11-10
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT07179939 2025-09-18
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase 2 Not yet recruiting
NCT04469764 2025-07-29
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT02476786 2025-07-28
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Washington University School of Medicine
Phase 2 Recruiting
NCT06953882 2025-07-14
SELECT
Yale University
Phase 2 Recruiting
NCT05472792 2025-05-23
CAMERAN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT05190094 2025-05-07
ICRG0201
International Cancer Research Group, United Arab Emirates
Phase 2 Recruiting
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03219476 2025-04-29
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT04294225 2025-01-28
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
Mayo Clinic
Phase 2 Completed
NCT04719273 2025-01-08
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
Thomas Jefferson University
Phase 2 Active not recruiting
NCT04256941 2024-12-27
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04985266 2024-12-05
TRAK-ER
Royal Marsden NHS Foundation Trust
Phase 2 Recruiting
NCT02188745 2024-07-17
POLLY
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT02648477 2024-03-19
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT04714619 2023-12-19
CAILA
MedSIR
Phase 2 Terminated
NCT02585388 2023-09-06
CHEOPS
ARCAGY/ GINECO GROUP
Phase 2 Terminated
NCT03555877 2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2 Completed
NCT00921115 2023-05-19
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
University of Kansas Medical Center
Phase 2 Completed
NCT00128843 2023-03-06
Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT02440230 2022-12-30
SEAT
Shanghai Jiao Tong University School of Medicine
Phase 2 Completed
NCT05411380 2022-11-04
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
Sun Yat-sen University
Phase 2 Unknown
NCT01989780 2022-08-04
BOOSTER
Japan Breast Cancer Research Group
Phase 2 Completed
NCT03874325 2022-05-31
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT02000596 2022-05-27
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
University of Maryland, Baltimore
Phase 2 Terminated
NCT01234532 2022-05-03
0927GCC
University of Maryland, Baltimore
Phase 2 Terminated
NCT04666961 2022-04-22
HORNEO01
Institut Cancerologie de l'Ouest
Phase 2 Recruiting
NCT02269670 2022-04-05
Phase II Study of Everolimus Beyond Progression
Emory University
Phase 2 Terminated
NCT00405938 2021-11-18
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02603679 2021-08-03
PREDIX LumB
Karolinska University Hospital
Phase 2 Active not recruiting
NCT00629616 2021-06-09
NIMFEA
UNICANCER
Phase 2 Completed
NCT00256217 2021-05-11
Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
University of California, Irvine
Phase 2 Completed
NCT00570323 2020-07-28
PACT001
Baylor Breast Care Center
Phase 2 Completed
NCT02592083 2020-07-07
PREDIX LumA
Karolinska University Hospital
Phase 2 Active not recruiting
NCT02291913 2020-02-17
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00186121 2019-10-07
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
Stanford University
Phase 2 Completed
NCT00179517 2019-07-17
Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo
Beth Israel Deaconess Medical Center
Phase 2 Completed